Afsar Barlas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Afsar Barlas has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Katia Manova-Todorova
Molecular Cytology Core Facility, and
58 shared publications - Eric Chan
Molecular Cytology Core, Memorial Sloan Kettering Cancer Center, New York, New York
57 shared publications - Mesruh Turkekul
11The Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York
46 shared publications - Aimee M. Crago
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
45 shared publications - Allison L. Richards
Memorial Sloan Kettering Cancer Center 2 Marie-Josée and Henry R. Kravis Center for Molecular Oncology New York, New York
45 shared publications - Andrew Koff
Memorial Sloan Kettering Cancer Center
45 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Video 1b from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with MEK inhibitor
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Video 1b from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with MEK inhibitor
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Video 1a from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with DMSO
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Video 1a from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with DMSO
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video-2 from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Time-lapse video with and without ERK inhibition
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video-2 from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Time-lapse video with and without ERK inhibition
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Video 1a from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with DMSO
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Video 1a from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with DMSO
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Video 1b from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with MEK inhibitor
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Video 1b from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with MEK inhibitor
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Video-2 from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Time-lapse video with and without ERK inhibition
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video-2 from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Time-lapse video with and without ERK inhibition